NMSC Coverage From Every Angle
Advertisement
Advertisement

Steven M. Horwitz, MD, on PTCL and CTCL: Trial Results on Cerdulatinib and NCCN Practice Guidelines

Posted: Tuesday, December 4, 2018

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase IIa study findings on the novel SYK/JAK inhibitor cerdulatinib for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma and how they relate to the NCCN Clinical Practice Guidelines.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.